The study will focus initially on the safety and tolerability of IQNLF, one component of IQ-DAA.
The study is being conducted by QPS Netherlands BV, and will initially involve 32 healthy volunteers.
IQ Therapeutics CEO Roland Lageveen said IQ Therapeutics is pleased to initiate this clinical trial which will provide valuable information regarding the safety and kinetics of IQ-DAA in humans, including an initial perspective of its potential to reach efficacious levels in humans.
"IQ-DAA contains two antibodies to neutralize Anthrax lethal toxin and it has been demonstrated to be very efficacious in animal models," Lageveen said.